Grail Encouraged By New Circulating Cell-free Genome Atlas Data
At the American Society of Clinical Oncology Annual Meeting on June 4, 2018, GRAIL announced the clinical results from a 127-patient sub-study of its Circulating Cell-free Genome Atlas (CCGA) trial. The analysis revealed that the company’s genome-sequencing blood tests can detect lung cancer with 98%...